Site Search

... Society Cancer Action Network (ACS CAN) in Indiana: "Biomarker testing and precision medicine are helping extend and improve lives by tailoring care and treatment to a person’s specific type of cancer. Over the past few months, we have heard countless stories of the difficulties patients ... this legislation. We urge the Governor to quickly sign this legislation into law so Indiana can take this significant step towards improving health outcomes and lowering health care costs." In 2024, approximately 14,280 Hoosiers will die from cancer. Improved access to biomarker testing can connect more patients to ...

... the last few decades and is increasingly important in the treatment of other conditions, providing access to targeted treatment and tailoring care to a person’s individual disease. Targeted therapies often result in improved quality of life and survivorship. For example, patients with ... survivor and Philadelphia local Michael Hu. “When I was first diagnosed with metastatic lung cancer, I can recall my sister, who works in health care, saying to me, ‘the treatment you start on matters.’ Throughout the last two years, her words have stuck with me,” said Hu. ... advocacy affiliate, ACS CAN has successfully advocated for billions of dollars in cancer research funding, expanded access to quality affordable health care, and advanced proven tobacco control measures. We stand with our volunteers, working to make cancer a top priority for policymakers in ...

... session, the American Cancer Society Cancer Action Network (ACS CAN) urges legislators to prioritize legislation that will improve access to care for cancer patients by expanding coverage for biomarker testing. “ACS CAN calls on the legislature to increase access to biomarker testing, an essential step in accessing precision medicine treatments by ensuring state regulated health insurance, including Medicaid, covers appropriate biomarker testing for patients who could benefit. Dubbed ‘the right treatment at the ... has played a critical role in improving cancer outcomes,” said Doug Hogan, ACS CAN government relations director. “Despite its benefits, health insurance coverage of biomarker testing has not kept pace with innovations in treatment.  Additionally, ACS CAN calls on the legislature to ...

... for the American Cancer Society Cancer Action Network (ACS CAN) in Connecticut: “Biomarker testing is essential to high-quality, personalized care for many conditions and can be a real gamechanger for many patients, but unfortunately, not everyone who can benefit from biomarker testing is getting it. There are significant disparities in health outcomes for Connecticut patients by race, income, and insurance type. Without addressing barriers to care, breakthroughs in personalized treatments could increase these disparities in health outcomes. “Expanding access to biomarker testing will help more people in Connecticut get the right treatment at the right time and avoid ...